Tumor Angiogenesis: How Cancer Hijacks Blood Vessel Formation

Added:

Vessel Co-option and Non-Angiogenic Tumor Growth

While classical tumor angiogenesis models emphasize the absolute necessity of sprouting new blood vessels to sustain tumor progression, "vessel co-option" presents a major alternative mechanism. In vessel co-option, cancer cells hijack pre-existing host vasculature instead of triggering new vessel formation. This non-angiogenic growth pattern is highly prevalent in well-vascularized organs such as the lung, liver, and brain. The existence of this mechanism explains why many tumors are intrinsically resistant to anti-angiogenic therapies (such as anti-VEGF drugs) or develop resistance over time. Consequently, cancer progression and metastasis can occur entirely independently of classical angiogenesis, challenging the paradigm that blockading new blood vessel growth is a universal bottleneck for tumor survival.

Basic structure and function of the circulatory system, specifically endothelial cells, capillaries, and their role in oxygen delivery.
Fundamentals of cancer biology, including uncontrolled cell division, primary tumor growth, and the general concept of metastasis.
Principles of cellular signaling, particularly how ligands bind to cell-surface receptors to trigger intracellular responses.
The concept of cellular hypoxia (oxygen deprivation) and how normal tissues respond to metabolic stress.
The molecular signaling cascade of HIF-1 (Hypoxia-Inducible Factor 1) and its transcriptional regulation of VEGF.
Mechanisms of anti-angiogenic cancer therapies (such as monoclonal antibodies like Bevacizumab) and the clinical challenges of drug resistance.
Alternative tumor vascularization pathways, including vessel co-option, intussusceptive angiogenesis, and vasculogenic mimicry.
Clinical imaging techniques (like functional MRI and PET scans) used to monitor tumor perfusion and the efficacy of anti-angiogenic drugs.
41.3K views959likes4:50@henrikslabOriginal Release: 2020-05-04

Tumor angiogenesis is the process by which tumors signal existing blood vessels to form new sprouts, primarily through the release of VEGF (Vascular Endothelial Growth Factor) by hypoxic tumor tissue; VEGF binds to receptors on endothelial cells, activating proteases that degrade the basement membrane and enabling tip cells to migrate toward the tumor, thereby supplying it with oxygen and glucose and facilitating potential metastasis.